MedTrace Logo

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

NCT05482789 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-04-20

No results posted yet for this study

Summary

This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, the investigators hope to find out if exenatide might also be helpful in gestational diabetes.

Conditions

  • Gestational Diabetes

Interventions

DRUG

Exenatide

10 microgram injected sub-cutaneously once

Sponsors & Collaborators

  • Maisa N. Feghali, MD

    lead OTHER

Principal Investigators

  • Maisa Feghali, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05482789 on ClinicalTrials.gov